Breast Cancer Research (Jan 2020)

Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer

  • Sunil Pancholi,
  • Mariana Ferreira Leal,
  • Ricardo Ribas,
  • Nikiana Simigdala,
  • Eugene Schuster,
  • Sophie Chateau-Joubert,
  • Lila Zabaglo,
  • Margaret Hills,
  • Andrew Dodson,
  • Qiong Gao,
  • Stephen R. Johnston,
  • Mitch Dowsett,
  • Sabina C. Cosulich,
  • Elisabetta Marangoni,
  • Lesley-Ann Martin

DOI
https://doi.org/10.1186/s13058-020-1254-5
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 1

Abstract

Read online

After publication of the original article [1], we were notified that an author’s surname has been erroneously spelled. Elisabetta Maragoni’s family name should be replaced with Marangoni.